Tyra Biosciences reports FY2025 net loss of $119.9M; cash $256M, outlines dabogratinib 3x3 strategy

Tyra Biosciences, Inc.

Q4 2025 net loss $33.8M vs $25.6M; FY net loss $119.9M vs $86.5M; R&D spend rose to $102.9M.
Cash, equivalents and marketable securities $256.0M at Dec 31, 2025; runway through at least 2027.
Launched 'dabogratinib 3x3' strategy: three pivotal-ready studies in LG-UTUC, IR NMIBC, and ACH.
SURF302 (IR NMIBC) initial 3-month CR data expected by end 1H 2026; BEACH301 (ACH) interim results 2H 2026.
Appointed Bhavesh Ashar as COO and Heather Faulds as Chief Regulatory Officer in Q4 2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.